Statin use and risk of prostate cancer: A Danish population-based case-control study, 1997-2010

Cancer Epidemiology

Volumn 38, Issue 1, 2014, Pages 42-47

  Jespersen, Christina G ^a   Nørgaard, Mette ^a   Friis, Søren ^b   Skriver, Charlotte ^b   Borre, Michael ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Hydroxymethylglutaryl CoA reductase inhibitors; Odds ratio; Pharmacoepidemiology; Prostate specific antigen; Prostatic neoplasm

Indexed keywords

HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ODDS RATIO; PHARMACOEPIDEMIOLOGY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DENMARK; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REGISTRIES; RISK; TIME FACTORS;

EID: 84894229646     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.10.010     Document Type: Article

References (38)

1. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376(9753):1670-1681.
2. Armitage J. The safety of statins in clinical practice. Lancet 2007, 370(9601):1781-1790.
3. Dimitroulakos J., Marhin W.H., Tokunaga J., Irish J., Gullane P., Penn L.Z., et al. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 2002, 4(4):337-346.
4. Hoque A., Chen H., Xu X.C. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2008, 17(1):88-94.
5. Weis M., Heeschen C., Glassford A.J., Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 2002, 105(6):739-745.
6. Alonso D.F., Farina H.G., Skilton G., Gabri M.R., De Lorenzo M.S., Gomez D.E. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998, 50(1):83-93.
7. Kusama T., Mukai M., Iwasaki T., Tatsuta M., Matsumoto Y., Akedo H., et al. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002, 122(2):308-317.
8. Platz E.A., Leitzmann M.F., Visvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006, 98(24):1819-1825.
9. Shannon J., Tewoderos S., Garzotto M., Beer T.M., Derenick R., Palma A., et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005, 162(4):318-325.
10. Murtola T.J., Tammela T.L., Lahtela J., Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007, 16(11):2226-2232.
11. Jacobs E.J., Rodriguez C., Bain E.B., Wang Y., Thun M.J., Calle E.E. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007, 16(11):2213-2217.
12. Friedman G.D., Flick E.D., Udaltsova N., Chan J., Quesenberry C.P., Habel L.A. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008, 17(1):27-36.
13. Murtola T.J., Tammela T.L., Maattanen L., Huhtala H., Platz E.A., Ala-Opas M., et al. Prostate cancer and PSA among statin users in the finnish prostate cancer screening trial. Int J Cancer 2010, 127(7):1650-1659.
14. Kaye J.A., Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004, 90(3):635-637.
15. Chang C.C., Ho S.C., Chiu H.F., Yang C.Y. Statins increase the risk of prostate cancer: a population-based case-control study. Prostate 2011, 71(16):1818-1824.
16. Jacobs E.J., Newton C.C., Thun M.J., Gapstur S.M. Long-term use of cholesterol-lowering drugs and cancer incidence in a large united states cohort. Cancer Res 2011, 71(5):1763-1771.
17. Agalliu I., Salinas C.A., Hansten P.D., Ostrander E.A., Stanford J.L. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008, 168(3):250-260.
18. Friis S., Poulsen A.H., Johnsen S.P., McLaughlin J.K., Fryzek J.P., Dalton S.O., et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005, 114(4):643-647.
19. Flick E.D., Habel L.A., Chan K.A., Van Den Eeden S.K., Quinn V.P., Haque R., et al. Statin use and risk of prostate cancer in the california men's health study cohort. Cancer Epidemiol Biomarkers Prev 2007, 16(11):2218-2225.
20. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., White C.M. Statins and cancer risk: a meta-analysis. JAMA 2006, 295(1):74-80.
21. Browning D.R., Martin R.M. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007, 120(4):833-843.
22. Kuoppala J., Lamminpaa A., Pukkala E. Statins and cancer. A systematic review and meta-analysis. Eur J Cancer 2008, 44(15):2122-2132.
23. Bonovas S., Filioussi K., Tsavaris N., Sitaras N.M. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 2006, 24(30):4808-4817.
24. Thygesen L.C., Ersboll A.K. Danish population-based registers for public health and health-related welfare research: introduction to the supplement. Scand J Public Health 2011, 39(Suppl. 7):8-10.
25. Pedersen C.B. The danish civil registration system. Scand J Public Health 2011, 39(Suppl. 7):22-25.
26. Storm H.H., Michelsen E.V., Clemmensen I.H., Pihl J. The danish cancer registry-history, content, quality and use. Dan Med Bull 1997, 44(5):535-539.
27. Outzen M., Brasso K., Martinussen N., Christensen J., Tjønneland A., Friis S., et al. Prostate cancer in Denmark 1978-2009 - trends in incidence and mortality. Acta Oncol 2013, 52(4):831-836.
28. Gjerstorff M.L. The danish cancer registry. Scand J Public Health 2011, 39(Suppl. 7):42-45.
29. Rothman K.J. Epidemiology-an introduction 2002, Oxford University Press, New York. 1st ed.
30. Kildemoes H.W., Sorensen H.T., Hallas J. The Danish national prescription registry. Scand J Public Health 2011, 39(Suppl. 7):38-41.
31. World Health Organization Collaborating Centre for Drug Statistics Methodology, Oslo, World health organization collaborating centre for drug statistics methodology, 2003. ATC classification index with DDDs. Updated 2012. http://www.whocc.no/atc_ddd_index/.
32. Jensen V.M., Rasmussen A.W. Danish education registers. Scand J Public Health 2011, 39(Suppl. 7):91-94.
33. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
34. Lynge E., Sandegaard J.L., Rebolj M. The Danish national patient register. Scand J Public Health 2011, 39(Suppl. 7):30-33.
35. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360(13):1320-1328.
36. Boudreau D.M., Yu O., Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010, 9(4):603-621.
37. Chang S.L., Harshman L.C., Presti J.C. Impact of common medications on serum total prostate-specific antigen levels: analysis of the national health and nutrition examination survey. J Clin Oncol 2010, 28(25):3951-3957.
38. Hamilton R.J., Goldberg K.C., Platz E.A., Freedland S.J. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008, 100(21):1511-1518.